Supercharged immune cells take on incurable tumors in early trial
NCT ID NCT04520711
First seen Nov 19, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-phase trial tests a new approach for people with incurable epithelial cancers. Patients receive specially engineered immune cells (TCR-T) that target unique markers on their tumors, plus two drugs that boost the immune response. The main goal is to check safety and find the right dose, while also tracking whether tumors shrink or stop growing. About 24 adults with advanced cancers that have not responded to standard treatments are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT EPITHELIAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.